HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions

[1] Xu B(2019)Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features Endocrine 64 97-108

[2] Reznik E(2017)Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 JAMA 317 1338-1348

[3] Tuttle RM(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[4] Knauf J(2006)Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining Mod Pathol 19 1631-1637

[5] Fagin JA(2014)The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations J Clin Endocrinol Metab 99 E276-E285

[6] Katabi N(2019)Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Update and Diagnostic Considerations-a Review Endocr Pathol 30 155-162

[7] Dogan S(2016)Noninvasive follicular thyroid neoplasm with papillary like nuclear features Endocr Relat Cancer. 23 893-897

[8] Aleynick N(2017)Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features Thyroid 27 512-517

[9] Seshan V(2018)Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma. Is NIFTP truly benign? World J Surg 42 321-326

[10] Middha S(2017)Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: The impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features Mod Pathol 30 810-825

[1] Xu B(2019)Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features Endocrine 64 97-108

[2] Reznik E(2017)Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 JAMA 317 1338-1348

[3] Tuttle RM(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[4] Knauf J(2006)Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining Mod Pathol 19 1631-1637

[5] Fagin JA(2014)The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations J Clin Endocrinol Metab 99 E276-E285

[6] Katabi N(2019)Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Update and Diagnostic Considerations-a Review Endocr Pathol 30 155-162

[7] Dogan S(2016)Noninvasive follicular thyroid neoplasm with papillary like nuclear features Endocr Relat Cancer. 23 893-897

[8] Aleynick N(2017)Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features Thyroid 27 512-517

[9] Seshan V(2018)Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma. Is NIFTP truly benign? World J Surg 42 321-326

[10] Middha S(2017)Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: The impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features Mod Pathol 30 810-825